Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Pfizer, Inc.
  6. Financials
    PFE   US7170811035

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization1 252 318216 827204 605221 725--
Entreprise Value (EV)1 275 225259 147232 220247 993242 741232 882
P/E ratio 23,3x13,7x21,5x13,4x14,0x14,2x
Yield 3,12%3,68%4,13%3,98%4,18%4,33%
Capitalization / Revenue 4,70x4,19x4,88x3,04x3,66x3,94x
EV / Revenue 5,13x5,01x5,54x3,40x4,01x4,14x
EV / EBITDA 12,6x12,3x13,0x9,04x9,21x9,51x
Price to Book 3,94x3,43x6,72x3,06x2,65x2,51x
Nbr of stocks (in thousands) 5 780 4755 534 1225 558 3975 597 694--
Reference price (USD) 43,739,236,839,639,639,6
Announcement Date 01/29/201901/28/202002/02/2021---
1 USD in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales1 53 64751 75041 90872 83860 52556 261
EBITDA1 21 81421 09717 80127 43626 35824 490
Operating profit (EBIT)1 20 04219 42013 02422 67820 23519 454
Operating Margin 37,4%37,5%31,1%31,1%33,4%34,6%
Pre-Tax Profit (EBT)1 11 88517 6827 49718 52218 68818 969
Net income1 11 15316 2739 61617 46616 08214 895
Net margin 20,8%31,4%22,9%24,0%26,6%26,5%
EPS2 1,872,871,712,952,832,80
Dividend per Share2 1,361,441,521,581,661,72
Announcement Date 01/29/201901/28/202002/02/2021---
1 USD in Million
2 USD
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2020 Q3 2020 Q4 2021 Q1 2021 Q2 2021 Q3 2021 Q4
Net sales1 12 13111 68414 58218 66319 57419 559
EBITDA1 5 5953 1146 8507 3557 3086 322
Operating profit (EBIT)1 4 3332 0685 6245 4955 7185 290
Operating Margin 35,7%17,7%38,6%29,4%29,2%27,0%
Pre-Tax Profit (EBT) ------
Net income1 2 1945944 8775 2415 0274 576
Net margin 18,1%5,08%33,4%28,1%25,7%23,4%
EPS2 0,390,100,860,760,770,67
Dividend per Share ------
Announcement Date 10/27/202002/02/202105/04/2021---
1 USD in Million
2 USD
Previous periodNext period
Balance Sheet Analysis
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt1 22 90742 32027 61526 26821 01611 158
Net Cash position1 ------
Leverage (Debt / EBITDA) 1,05x2,01x1,55x0,96x0,80x0,46x
Free Cash Flow1 13 78510 41212 15112 57516 08318 237
ROE (Net Profit / Equities) 16,6%25,7%15,2%29,3%25,0%22,0%
Shareholders' equity1 67 35763 27563 18059 57964 20167 812
ROA (Net Profit / Asset) 6,73%9,96%5,98%11,3%10,6%10,1%
Assets1 165 609163 456160 910154 391151 342147 935
Book Value Per Share2 11,111,45,4812,915,015,8
Cash Flow per Share2 2,652,222,562,133,203,32
Capex1 2 0422 1762 2522 5562 4022 328
Capex / Sales 3,81%4,20%5,37%3,51%3,97%4,14%
Announcement Date 01/29/201901/28/202002/02/2021---
1 USD in Million
2 USD
Analysis
AstraZeneca : GSK to boost spending power of pharma business post break-up
Key data
Capitalization (USD) 221 724 654 071
Net sales (USD) 41 908 000 000
Number of employees 78 500
Sales / Employee (USD) 533 860
Free-Float 59,2%
Free-Float capitalization (USD) 131 306 943 091
Avg. Exchange 20 sessions (USD) 986 207 390
Average Daily Capital Traded 0,44%
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA